886844-09-3Relevant academic research and scientific papers
Selective synthesis of benzyl enol ethers of β-dicarbonyl compounds in basic condition and the application towards synthesis of naphthoquinones
Katakawa, Kazuaki,Yonenaga, Dai,Terada, Tomoyo,Aida, Naoya,Sakamoto, Airi,Hoshino, Keishi,Kumamoto, Takuya
, p. 817 - 825 (2014)
Selective synthesis of benzyl enol ether of β-tetronic acids and β-dicarbonyl compounds in basic condition was examined. Benzylation of α-methyl-β-tetronic acid with benzyl tosylate in the presence of potassium carbonate gave the corresponding benzyl enol ether exclusively. The reaction of β-tetronic acid and cyclic 1,3-diketones gave the O-benzyl adducts preferentially than the C,O-dibenzylated ones. Diels-Alder reaction of furan derived the benzyl enol ether of α-methyl-β-tetronic acid and benzyne furnished the functionalized napthoquinone derivatives.
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
-
Paragraph 0321; 0322, (2014/08/19)
This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
-
Page/Page column 77, (2014/08/20)
This invention relates to substituted bicyclic dihydropyrimidinones of formula (I) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
